亚临床甲状腺功能减退症中甲状腺激素替代治疗的决定因素:基于多中心电子健康记录的研究
这项基于电子健康记录的观察性队列研究纳入美国与墨西哥四个学术中心2016年1月1日至2018年12月31日诊断的796例亚临床甲状腺功能减退症成人患者,其中165例(20.7%)接受甲状腺激素替代治疗。治疗组仅46.7%、未治疗组65.6%在决定治疗前有确认性甲状腺功能检查,甲状腺自身免疫评估使用不足。
要点
- 796例亚临床甲状腺功能减退症患者中165例(20.7%)接受甲状腺激素替代治疗。
- 女性(OR=1.71)和基线促甲状腺激素水平(每SD 2.75 mIU/L,OR=1.97)与更高治疗几率相关。
- 治疗组仅46.7%、未治疗组65.6%在决定治疗前有确认性甲状腺功能检查。
核心结论
- 在亚临床甲状腺功能减退症患者中,女性和基线促甲状腺激素水平与更高的治疗几率相关。
- 在该研究人群中,决定治疗或不治疗亚临床甲状腺功能减退症常仅基于一组异常甲状腺功能检查,且甲状腺自身免疫评估使用不足。
研究设计与样本
- 基于电子健康记录的观察性队列研究,纳入美国与墨西哥四个学术中心2016年1月1日至2018年12月31日诊断的亚临床甲状腺功能减退症成人患者。
- 共纳入796例患者(65.2%为女性),其中165例(20.7%)接受甲状腺激素替代治疗。
主要发现
- 治疗组较未治疗组更年轻(51.0岁[标准差18.3] vs 55.3岁[标准差18.2],p=0.008),女性比例更高(72.7% vs 63.2%,p=0.03)。
- 治疗组仅46.7%、未治疗组65.6%在决定开始甲状腺激素替代治疗前有确认性甲状腺功能检查。
- 甲状腺自身免疫评估频率无差异,但治疗组甲状腺自身免疫试验阳性率高于未治疗组(48.2% vs 20.3%,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The frequency and factors associated with thyroid hormone replacement therapy among patients with subclinical hypothyroidism (SCH) remain uncertain. Methods: In this electronic health records-based observational cohort study, we included adults diagnosed with SCH from four academic centers (the United States and Mexico) from January 1, 2016, to December 31, 2018. We aimed to identify the determinants of thyroid hormone replacement therapy for SCH and the frequency of treated SCH. Results: A total of 796 patients (65.2% women) had SCH, and 165 (20.7%) were treated with thyroid hormone replacement therapy. The treated group was younger [51.0 (standard deviation {SD} 18.3) vs. 55.3 (SD 18.2) years, p = 0.008] and had a higher proportion of women (72.7% vs. 63.2%, p = 0.03) compared with the untreated group. Only 46.7% of patients in the treated group and 65.6% in the untreated group had confirmatory thyroid function tests (TFTs) before the decision to start thyroid hormone replacement therapy was made. There was no difference in the frequency of thyroid autoimmunity evaluation, but a positive thyroid autoimmunity test was more frequent in the treated group compared with the untreated group (48.2% vs. 20.3%, p < 0.001). In a multivariable logistic regression model, female sex (odds ratio [OR] = 1.71 [CI 1.13-2.59], p = 0.01) and index thyrotropin (TSH) level (OR = 1.97 [CI 1.56-2.49], p < 0.001 for every SD [2.75 mIU/L] change) were associated with higher odds of treatment. Conclusions: Among patients with SCH, female sex and index TSH level were associated with higher odds of treatment. Moreover, in our population, the decision to treat or not to treat SCH was often based on only one set of abnormal TFTs, and thyroid autoimmunity assessment was underused.
引用
- Toloza FJK, El Kawkgi OM, Spencer HJ, et al. Determinants for Thyroid Hormone Replacement Therapy in Subclinical Hypothyroidism: A Multicenter Electronic Health Records-Based Study. Thyroid. 2023. PMID: 37279296. doi:10.1089/thy.2023.0062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。